Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: A multicentre pilot study

HIV Medicine

Volumn 9, Issue 7, 2008, Pages 508-513

  Llibre, Josep M ^a   Bonjoch, A ^a   Iribarren, J ^b   Galindo, M J ^c   Negredo, E ^a   Domingo, P ^d,i   Perez Alvarez N ^a,e   Martinez Picado, J ^f,g   Schapiro, J ^h,i   Clotet, B ^a,g,i   Alcaraz, C ⁱ   Arazo, P ⁱ   Cervantes, M ⁱ   Fuster, M ⁱ   Iribarren, J A ⁱ   Marino A ⁱ   Miralles, C ⁱ   Moreno, S ⁱ   Ocampo, A ⁱ   del Pozo, M A ⁱ   Puig, T ⁱ   Sambeat, M A ⁱ   Viciana, I ⁱ   Cortina, L ⁱ   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL SANT PAU   (Spain)

^e UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g IrsiCaixa Foundation   (Spain)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ NONE

Author keywords

HIV 1 resistance; Holding regimen; Multidrug failure; Tenofovir; Zidovudine

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; THYMIDINE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; THYMIDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 50149119269     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00581.x     Document Type: Article

References (25)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov.
2. Kantor R, Shafer RW, Follansbee S et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18: 1503-1511.
3. Cozzi-Lepri A, Phillips AN, Ruiz L et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21: 721-732.
4. Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen. Clin Infect Dis 2007; 45: 1085-1092.
5. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
6. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
7. Ruiz L, Paredes R, Gomez G et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21: 169-178.
8. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V Study). AIDS 2006; 20: 795-803.
9. Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS 2001; 15: 117-119.
10. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 1537-1544.
11. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004; 37 (Suppl. 1): 36-43.
12. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
13. White KL, Margot NA, Ly JK et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005; 19: 1751-1760.
14. Diallo K, Oliveira M, Moisi D et al. Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002; 46: 2254-2256.
15. Diallo K, Marchand B, Wei X et al. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol 2003; 77: 8621-8632.
16. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007; 21: 1405-1414.
17. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antiviral Ther 2007; 12: 695-703.
18. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 971-977.
19. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007; 21: 665-675.
20. Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6: 22-33.
21. Ross L, Parkin N, Chappey C et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18: 1691-1696.
22. Morand-Joubert L, Charpentier C, Poizat G et al. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Antiviral Ther 2006; 11: 143-154.
23. Eron JJ Jr, Bartlett JA, Santana JL et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37: 1581-1583.
24. Latham V, Stebbing J, Mandalia S et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 2005; 56: 186-189.
25. Hunt PW, Deeks SG, Bangsberg DR et al. The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006; 20: 691-699.